Bortezomib, cyclophosphamide + prednisone in refractory MM

By  

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Bortezomib boosts melphalan plus prednisone for MM

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Bortezomib–Dexamethasone or Vincristine–Doxorubicin–Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients

By Chen RA   Tu Y   Cao Y   Liu L   Liang Y  

The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. : 1975-1984

Field House Publishing

Access to resources Recommend Favorite

The US FDA has granted priority review for bortezomib [Velcade] for the treatment of patients with newly diagnosed multiple myeloma (MM).

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Doxorubicin: Progression of liver cancer following TACE: case report

By  

Reactions Weekly, Vol. 1, Iss. 1316, 2010-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite